Forced expression of Nanog with mRNA synthesized in vitro to evaluate the malignancy of HeLa cells through acquiring cancer stem cell phenotypes

Oncol Rep. 2016 May;35(5):2643-50. doi: 10.3892/or.2016.4639. Epub 2016 Feb 26.

Abstract

Nanog is a pluripotency-related factor. It was also found to play an important role in tumorigenesis. To date, the mechanisms underlying cervical tumorigenesis still need to be elucidated. In the present study, Nanog mRNA was synthesized in vitro and transfected into HeLa cells. After mRNA transfection, the forced expressed of Nanog in HeLa cells led to markedly increased invasion, migration, resistance to chemotherapeutic agents and dedifferentiation. In a subcutaneous xenograft assay, these cells had significantly increased tumorigenic capacity. Real-time PCR indicated that Nanog‑induced dedifferentiation was associated with increased expression of endogenous Oct4, Sox2 and FoxD3. In addition, the dedifferentiated HeLa cells acquired features associated with cancer stem cells (CSCs), such as multipotent differentiation capacity, and expression of CSC markers such as CD133. These data imply that Nanog is a positive regulator of cervical cancer dedifferentiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Cell Survival / drug effects
  • Cell Transformation, Neoplastic
  • Cisplatin / pharmacology
  • Female
  • Gene Expression
  • HeLa Cells
  • Humans
  • Mice, Nude
  • Nanog Homeobox Protein / genetics*
  • Nanog Homeobox Protein / metabolism
  • Neoplasm Transplantation
  • Neoplastic Stem Cells / physiology*
  • Paclitaxel / pharmacology
  • Phenotype
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • NANOG protein, human
  • Nanog Homeobox Protein
  • RNA, Messenger
  • Paclitaxel
  • Cisplatin